The Kanjinti stability study has recently been published in the Generics and Biosimilars Initiative Journal (GaBI Journal) and can be found here:
QCNW-Liverpool completed a large study on the stability and continued potency of patient preparations of the Trastuzumab biosimilar Kanjinti, with the support of Amgen. The study covered a range of concentratio...
Read Full Story
The Pemetrexed study has now been reported in the European Journal of Hospital Pharmacy and can be found here.
QCNW-Liverpool has recently completed a stability study on Panitumumab preparations, which was undertaken at the request of Clatterbridge Cancer Centre and supported by Amgen®. Amgen Ltd had no input on either the study design or results. A copy of the report has been supplied to the NHS Pharmaceutical Research and Development Working Group for review, with the intention the report can be utilised by the wider NHS pharmacy community.
QCNW-Liverpool has worked on the formulation of a Vancomycin Eye Drop preparation to establish a preparation with both good preservative efficacy and chemical stability. Carrying out the study on behalf of North West of England NHS Pharmacy Services, the laboratory has now supplied a report on both preservative efficacy and stability of the Vancomycin Eye Drop preparation. This work continues the laboratory's collaboration with the local NHS unit to help ensure ocular preparations ...
Read Full Story
QCNW-Liverpool have recently completed a stability study on Pemetrexed preparations for NHS England. The report generated has been reviewed within the NHS Pharmacy R&D Group and circulated within the NHS. If you wish to have a copy of the report please use the ‘Contact’ section of the website.
Dr Lyndsay Davies has been a member of the NHS Pharmaceutical Research and Development Working Group since 2018. Lyndsay brings significant expertise to the group, particularly in the area of testing of biological molecules such monoclonal antibodies. In January 2020 Lyndsay was a presenter at UCLAN’s symposium:- Your Product in Their Hands: Toward predicting biopharmaceutical aggregation in practice and use.
Following a recent inspection QCNW-Liverpool has successfully transitioned to the updated ISO 17025:2017 standard for accreditation as a testing laboratory. This is a demonstration of the commitment of the laboratories to continue to develop and improve and of the staff continued support and hard work.
In November 2019 Luke Nelson presented a poster on ‘Supply of OPAT Presentations’ at the ‘NHS Pharmaceutical Quality Assurance and Technical Services Symposium’.